LifeMD, Inc.

LifeMD, Inc. announced it will report its financial results for the second quarter and first six months ended June 30, 2026, after the U.S. financial markets close on August 5, 2026. The company will host a conference call and webcast on the same day at 4:30 p.m. Eastern time to discuss the results.

LifeMD, Inc. announced a strategic co-marketing collaboration with Halozyme's wholly owned subsidiary, Antares Pharma, Inc. LifeMD will serve as the exclusive telehealth co-marketing partner for the XYOSTED self-pay program, an FDA-approved once-weekly subcutaneous testosterone auto-injector. The program, launching in July 2026 in 37 states, aims to expand access to hypogonadism treatment through virtual evaluations, preferred pharmacy dispensing, and consumer education, all for a transparent monthly price of approximately $249.

LifeMD, Inc. announced the appointment of Umesh Sripad as its new Chief Technology Officer (CTO), effective immediately. Mr. Sripad will be responsible for leading the company's technology strategy, platform transformation, AI enablement, cybersecurity, and data infrastructure as LifeMD continues its rapid expansion. He brings over two decades of experience from prominent companies like PetMeds, Bed Bath & Beyond, and IKEA USA, and his expertise is expected to be invaluable as LifeMD aims to scale its platform to serve millions of patients. As an inducement for his employment, Mr. Sripad was granted 150,000 restricted stock units, with vesting tied to both continued service and performance targets.

LifeMD, Inc. announced that its management will participate in two upcoming investor conferences. The company will attend the LD Micro Invitational XVI Conference from May 17-19, 2026, where management will present on May 19th and be available for one-on-one meetings. Following this, LifeMD management will participate in the B. Riley Securities 26th Annual Investor Conference on May 20-21, 2026, holding one-on-one meetings on May 20th.

LifeMD, Inc. reported a significant increase in net loss attributable to common stockholders, reaching $9.65 million for Q1 2026, compared to a $0.96 million loss in Q1 2025. Telehealth revenue slightly decreased to $50.16 million. The company also disclosed non-compliance with a Consolidated Interest Coverage Ratio covenant under its new $30 million credit facility, primarily due to a 34% increase in selling and marketing expenses. Discussions with Citizens Bank for an amendment or waiver are ongoing.

LifeMD reported Q1 2026 revenue of $50.2 million, exceeding its guidance, and an adjusted EBITDA loss of $4.5 million, in line with expectations. The company achieved record net telehealth subscriber additions, ending the quarter with over 365,000 subscribers, and saw significant growth in its weight management and women's health segments. LifeMD affirmed its full-year 2026 revenue and adjusted EBITDA guidance, highlighting strategic investments for future growth and platform expansion.

LifeMD, Inc. reported strong first-quarter 2026 financial results, with revenue of $50.2 million, surpassing its guidance. The company achieved a significant gross margin expansion to 88% and recorded its largest quarterly net addition of over 42,000 telehealth subscribers, bringing the total to over 365,000. Key growth areas like GLP-1 weight management and Women’s Health saw substantial patient sign-up increases. LifeMD exited the quarter with a healthy cash balance of $34.5 million and no debt, while affirming its full-year 2026 financial guidance.

LifeMD, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 12, 2026, at 12:00 p.m. EDT. Stockholders of record as of April 22, 2026, are entitled to vote on several key proposals. These include the election of seven directors, the ratification of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2026, and the approval of the Fourth Amended and Restated 2020 Equity and Incentive Plan. The proposed equity plan amendments involve increasing the maximum number of shares available for issuance by 3,000,000, removing the annual increase feature, and prohibiting repricing of options and stock appreciation rights without stockholder approval.

LifeMD, Inc. announced it will report its financial results for the first quarter ended March 31, 2026, after the close of U.S. financial markets on May 6, 2026. The company will host a conference call and webcast on the same day at 4:30 p.m. Eastern time to discuss the results.

LifeMD, Inc. has begun offering Foundayo™ (orforglipron), Eli Lilly's newly FDA-approved once-daily oral GLP-1 treatment, to eligible patients via its weight management program. This strategic move, facilitated through integration with LillyDirect®, expands LifeMD's portfolio of branded GLP-1 therapies and reinforces its position in the virtual weight management market. Foundayo is available at a starting self-pay price of $149 per month, with potential for commercially insured patients to pay as little as $25, and Medicare coverage expected by July 2026. The addition of Foundayo, approved on April 1, 2026, is expected to enhance patient access to affordable, high-quality weight management care.